Crinetics Pharmaceuticals (CRNX) Assets Average (2018 - 2026)

Crinetics Pharmaceuticals has reported Assets Average for 9 years, with the latest figure at $1.3 billion in Q1 2026.

• For the quarter ending Q1 2026, Assets Average fell 9.6% year-over-year to $1.3 billion; the trailing twelve-month figure through Mar 2026 stood at $1.3 billion (down 9.6% YoY), and the FY2025 full-year result was $1.3 billion, up 23.72% from the prior year.
• Assets Average for Q1 2026 stood at $1.3 billion, up from $1.2 billion in the prior quarter.
• The five-year high for Assets Average was $1.4 billion in Q1 2025, with the low at $303.6 million in Q2 2023.
• Average Assets Average over 5 years is $794.8 million, with a median of $806.8 million recorded in 2024.
• Year-over-year, Assets Average fell 19.57% in 2023 and soared 215.13% in 2024.
• Tracing CRNX's Assets Average over 5 years: stood at $368.5 million in 2022, then jumped by 73.24% to $638.4 million in 2023, then jumped by 85.76% to $1.2 billion in 2024, then slipped by 2.09% to $1.2 billion in 2025, then gained by 8.84% to $1.3 billion in 2026.
• The last three Assets Average figures came in at $1.3 billion (Q1 2026), $1.2 billion (Q4 2025), and $1.2 billion (Q3 2025), per Business Quant data.

Peer Comparison